Vaccinex to delist common stock from Nasdaq

Vaccine announced that it has notified Nasdaq of its decision to delist the company’s shares of common stock, par value $0.0001 per share, from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024.